⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735080 | 0.59 | — | — | |
| SCHEMBL13451511 | 0.59 | — | — | |
| SCHEMBL5358828 | 0.57 | — | — | |
| SCHEMBL2206771 | 0.52 | — | — | |
| SCHEMBL2601688 | 0.52 | — | — | |
| SCHEMBL6850987 | 0.52 | GSK3A (0.44) | — | |
| SCHEMBL4409585 | 0.51 | GSK3A (0.32) | — | |
| SCHEMBL9754806 | 0.51 | — | — | |
| SCHEMBL619767 | 0.50 | — | — | |
| SCHEMBL133474 | 0.48 | GSK3A (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029944-A1 | Process for the Synthesis of Solifenacin | CORPORACION MEDICHEM, S.L. (ES) | 2010-02-04 | — | — | US | claimed |
| EP-2102200-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF SOLIFENACIN | Medichem, S.A. (ES) | 2009-09-23 | — | — | EP | claimed |
| WO-2008062282-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF SOLIFENACIN | MEDICHEM S.A. (ES) | 2008-05-29 | — | — | WO | claimed |
| US-6057096-A | NONRADIOACTIVE METHOD BY CONJUGATING LABELING AGENT TO ONE OR MORE OLIGONUCLEOTIDE PRIMERS, AMPLIFYING A NUCLEIC ACID SEQUENCE WITH PRIMERS, TREATING AMPLIFIED SEQUENCES WITH ELECTROMAGNETIC RADIATION | THE TRUSTEES OF BOSTON UNIVERSITY (US) | 2000-05-02 | — | — | US | claimed |
| US-5986076-A | A CONJUGATE IS FORMED BY BONDING A BIOREACTIVE AGENT TO THE THERAPEUTIC AGENT WITH A BOND THAT IS SELECTIVELY CLEAVABLE WITH ELECTROMAGNETIC RADIATION; USEFUL FOR CONTROLLED RELEASE OF DRUGS TO TREAT THE DISORDER | TRUSTEES OF BOSTON UNIVERSITY (US) | 1999-11-16 | — | — | US | claimed |
| US-20240124389-A1 | COMPOUND OR SALT THEREOF, LIPID PARTICLES, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2024-04-18 | — | — | US | disclosed |
| EP-4332086-A1 | COMPOUND OR SALT THEREOF, LIPID PARTICLES, AND PHARMACEUTICAL COMPOSITION | FUJIFILM Corporation (JP) | 2024-03-06 | — | — | EP | disclosed |
| EP-4328309-A2 | LIPID COMPOSITION | FUJIFILM Corporation (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-4059505-B1 | LIPID COMPOSITION | FUJIFILM CORP (JP) | 2024-02-21 | — | — | EP | disclosed |
| CN-117279888-A | Compound or salt thereof, lipid particle and pharmaceutical composition | 富士胶片株式会社 | 2023-12-22 | — | — | CN | disclosed |
| EP-3805198-B1 | COMPOUND, SALT THEREOF AND LIPID PARTICLES | FUJIFILM CORP (JP) | 2023-09-20 | — | — | EP | disclosed |
| EP-3981435-B1 | LIPID COMPOSITION | FUJIFILM CORP (JP) | 2023-08-16 | — | — | EP | disclosed |
| WO-2021095876-A1 | LIPID COMPOSITION | 富士フイルム株式会社 | 2021-05-20 | — | — | WO | disclosed |
| EP-3805198-A1 | COMPOUND, SALT THEREOF AND LIPID PARTICLES | FUJIFILM Corporation (JP) | 2021-04-14 | — | — | EP | disclosed |
| US-20210085604-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | FUJIFILM CORPORATION (JP) | 2021-03-25 | — | — | US | disclosed |
| WO-2020246581-A1 | LIPID COMPOSITION | 富士フイルム株式会社 | 2020-12-10 | — | — | WO | disclosed |
| US-20140228575-A1 | Process for the Preparation of Solifenacin and Salts Thereof | ISOCHEM (FR) | 2014-08-14 | — | — | US | disclosed |
| US-20100029944-A1 | Process for the Synthesis of Solifenacin | CORPORACION MEDICHEM, S.L. (ES) | 2010-02-04 | — | — | US | disclosed |
| EP-2102200-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF SOLIFENACIN | Medichem, S.A. (ES) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008062282-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF SOLIFENACIN | MEDICHEM S.A. (ES) | 2008-05-29 | — | — | WO | disclosed |